25 XP   0   0   10

Supernus Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyse Supernus together

PenkeI guess you are interested in Supernus Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Supernus Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Supernus Pharmaceuticals Inc

I send you an email if I find something interesting about Supernus Pharmaceuticals Inc.

Quick analysis of Supernus (30 sec.)










What can you expect buying and holding a share of Supernus? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$16.66
Expected worth in 1 year
$19.05
How sure are you?
82.5%

+ What do you gain per year?

Total Gains per Share
$2.39
Return On Investment
8.2%

For what price can you sell your share?

Current Price per Share
$29.31
Expected price per share
$26.47 - $35.44
How sure are you?
50%

1. Valuation of Supernus (5 min.)




Live pricePrice per Share (EOD)

$29.31

Intrinsic Value Per Share

$24.68 - $36.77

Total Value Per Share

$41.34 - $53.44

2. Growth of Supernus (5 min.)




Is Supernus growing?

Current yearPrevious yearGrowGrow %
How rich?$921.5m$849m$67.3m7.4%

How much money is Supernus making?

Current yearPrevious yearGrowGrow %
Making money$329k$9.3m-$9m-2,752.4%
Net Profit Margin0.2%5.6%--

How much money comes from the company's main activities?

3. Financial Health of Supernus (5 min.)




What can you expect buying and holding a share of Supernus? (5 min.)

Welcome investor! Supernus's management wants to use your money to grow the business. In return you get a share of Supernus.

What can you expect buying and holding a share of Supernus?

First you should know what it really means to hold a share of Supernus. And how you can make/lose money.

Speculation

The Price per Share of Supernus is $29.31. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Supernus.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Supernus, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $16.66. Based on the TTM, the Book Value Change Per Share is $0.60 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.16 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Supernus.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.020.1%0.000.0%0.150.5%0.301.0%0.281.0%
Usd Book Value Change Per Share0.000.0%0.602.0%-0.16-0.5%0.421.4%0.401.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.000.0%0.602.0%-0.16-0.5%0.421.4%0.401.4%
Usd Price Per Share28.94-30.70-32.69-28.67-27.40-
Price to Earnings Ratio340.51--36.18-131.39-37.19-38.17-
Price-to-Total Gains Ratio-14,158.05--3,557.68--11.46--703.73--316.80-
Price to Book Ratio1.74-1.92-2.24-2.19-5.33-
Price-to-Total Gains Ratio-14,158.05--3,557.68--11.46--703.73--316.80-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share29.31
Number of shares34
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.600.42
Usd Total Gains Per Share0.600.42
Gains per Quarter (34 shares)20.3214.26
Gains per Year (34 shares)81.2657.03
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10817105747
201631520114104
302442330171161
403253140228218
504063950285275
604884760342332
705695570399389
806506380456446
907317190513503
1008138000570560

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share2.02.00.050.0%10.02.00.083.3%18.02.00.090.0%37.03.00.092.5%39.015.01.070.9%
Book Value Change Per Share2.02.00.050.0%7.04.01.058.3%15.04.01.075.0%33.05.02.082.5%38.013.04.069.1%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.055.00.0%
Total Gains per Share2.02.00.050.0%7.04.01.058.3%15.04.01.075.0%33.05.02.082.5%38.013.04.069.1%

Fundamentals of Supernus

About Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.

Fundamental data was last updated by Penke on 2024-04-12 19:25:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is not making a profit/loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is cheap.

1.1. Profitability of Supernus Pharmaceuticals Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Supernus earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Supernus to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 0.7% means that $0.01 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Supernus Pharmaceuticals Inc:

  • The MRQ is 0.7%. The company is not making a profit/loss.
  • The TTM is 0.2%. The company is not making a profit/loss.
Trends
Current periodCompared to+/- 
MRQ0.7%TTM0.2%+0.5%
TTM0.2%YOY5.6%-5.4%
TTM0.2%5Y13.6%-13.4%
5Y13.6%10Y16.2%-2.7%
1.1.2. Return on Assets

Shows how efficient Supernus is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Supernus to the Drug Manufacturers - Specialty & Generic industry mean.
  • 0.1% Return on Assets means that Supernus generated $0.00 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Supernus Pharmaceuticals Inc:

  • The MRQ is 0.1%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is -0.1%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ0.1%TTM-0.1%+0.2%
TTM-0.1%YOY0.6%-0.6%
TTM-0.1%5Y1.2%-1.3%
5Y1.2%10Y3.1%-1.9%
1.1.3. Return on Equity

Shows how efficient Supernus is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Supernus to the Drug Manufacturers - Specialty & Generic industry mean.
  • 0.1% Return on Equity means Supernus generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Supernus Pharmaceuticals Inc:

  • The MRQ is 0.1%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 0.0%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ0.1%TTM0.0%+0.1%
TTM0.0%YOY1.1%-1.0%
TTM0.0%5Y2.5%-2.5%
5Y2.5%10Y5.0%-2.5%

1.2. Operating Efficiency of Supernus Pharmaceuticals Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Supernus is operating .

  • Measures how much profit Supernus makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Supernus to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 11.6% means the company generated $0.12  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Supernus Pharmaceuticals Inc:

  • The MRQ is 11.6%. The company is operating less efficient.
  • The TTM is 3.0%. The company is operating less efficient.
Trends
Current periodCompared to+/- 
MRQ11.6%TTM3.0%+8.5%
TTM3.0%YOY8.5%-5.5%
TTM3.0%5Y21.1%-18.1%
5Y21.1%10Y19.5%+1.5%
1.2.2. Operating Ratio

Measures how efficient Supernus is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 0.88 means that the operating costs are $0.88 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Supernus Pharmaceuticals Inc:

  • The MRQ is 0.884. The company is less efficient in keeping operating costs low.
  • The TTM is 0.984. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.884TTM0.984-0.099
TTM0.984YOY0.925+0.059
TTM0.9845Y0.817+0.166
5Y0.81710Y0.819-0.002

1.3. Liquidity of Supernus Pharmaceuticals Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Supernus is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.70 means the company has $1.70 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Supernus Pharmaceuticals Inc:

  • The MRQ is 1.699. The company is able to pay all its short-term debts. +1
  • The TTM is 1.537. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.699TTM1.537+0.163
TTM1.537YOY1.185+0.352
TTM1.5375Y2.070-0.533
5Y2.07010Y2.399-0.329
1.3.2. Quick Ratio

Measures if Supernus is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Supernus to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 1.99 means the company can pay off $1.99 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Supernus Pharmaceuticals Inc:

  • The MRQ is 1.995. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 1.484. The company is able to pay all its short-term debts with the most liquid assets. +1
Trends
Current periodCompared to+/- 
MRQ1.995TTM1.484+0.511
TTM1.484YOY1.385+0.099
TTM1.4845Y2.366-0.882
5Y2.36610Y2.784-0.418

1.4. Solvency of Supernus Pharmaceuticals Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Supernus assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Supernus to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.35 means that Supernus assets are financed with 34.6% credit (debt) and the remaining percentage (100% - 34.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Supernus Pharmaceuticals Inc:

  • The MRQ is 0.346. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.354. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.346TTM0.354-0.008
TTM0.354YOY0.499-0.145
TTM0.3545Y0.475-0.121
5Y0.47510Y0.457+0.018
1.4.2. Debt to Equity Ratio

Measures if Supernus is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Supernus to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 52.9% means that company has $0.53 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Supernus Pharmaceuticals Inc:

  • The MRQ is 0.529. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.577. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.529TTM0.577-0.048
TTM0.577YOY0.998-0.421
TTM0.5775Y0.936-0.359
5Y0.93610Y0.907+0.030

2. Market Valuation of Supernus Pharmaceuticals Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Supernus generates.

  • Above 15 is considered overpriced but always compare Supernus to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 340.51 means the investor is paying $340.51 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Supernus Pharmaceuticals Inc:

  • The EOD is 344.868. Based on the earnings, the company is expensive. -2
  • The MRQ is 340.515. Based on the earnings, the company is expensive. -2
  • The TTM is -36.177. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD344.868MRQ340.515+4.354
MRQ340.515TTM-36.177+376.692
TTM-36.177YOY131.390-167.567
TTM-36.1775Y37.189-73.366
5Y37.18910Y38.167-0.977
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Supernus Pharmaceuticals Inc:

  • The EOD is 9.006. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 8.892. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is 2.355. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD9.006MRQ8.892+0.114
MRQ8.892TTM2.355+6.537
TTM2.355YOY17.189-14.834
TTM2.3555Y9.017-6.662
5Y9.01710Y22.865-13.848
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Supernus is to cheap or to expensive compared to its book value.

Let's take a look of the Price to Book Ratio trends of Supernus Pharmaceuticals Inc:

  • The EOD is 1.759. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.737. Based on the equity, the company is underpriced. +1
  • The TTM is 1.915. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.759MRQ1.737+0.022
MRQ1.737TTM1.915-0.178
TTM1.915YOY2.241-0.325
TTM1.9155Y2.189-0.274
5Y2.18910Y5.329-3.140
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Supernus Pharmaceuticals Inc.

3.1. Institutions holding Supernus Pharmaceuticals Inc

Institutions are holding 107.863% of the shares of Supernus Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31BlackRock Inc18.96920.0077103827702028651.9928
2023-12-31Vanguard Group Inc11.35420.003962147311425512.3476
2023-12-31Armistice Capital, LLC8.49551.83714650000-442000-8.6803
2023-12-31Macquarie Group Ltd5.00180.09152737716-13140-0.4777
2023-12-31Dimensional Fund Advisors, Inc.4.48780.020824563691415866.1166
2023-12-31State Street Corporation3.76780.002920623261453167.5803
2023-12-31Polar Capital Holdings PLC3.54320.3438193936528489517.2197
2023-12-31Stephens Inv Mgmt Group LLC3.48020.8059190486420016611.742
2023-12-31Loomis, Sayles & Company LP2.98980.07251636490-93779-5.4199
2023-12-31Renaissance Technologies Corp2.51840.06181378422-60000-4.1712
2023-12-31GW&K Investment Management, LLC2.40710.35551317526-88632-6.3031
2023-12-31Geode Capital Management, LLC2.27490.0038124515415205713.9107
2023-12-31Aristotle Capital Boston, LLC2.1191.0261159828-28153-2.3698
2023-12-31Pictet Asset Manangement SA1.91120.0334104608212553013.6364
2023-12-31Congress Asset Management Company, LLP1.68230.209892080836440.3973
2023-12-31Ashford Capital Management Inc1.513.2044826488-90259-9.8456
2023-12-31Morgan Stanley - Brokerage Accounts1.32160.001872335519477636.849
2023-12-31Victory Capital Management Inc.1.26130.021690398-20771-2.9207
2023-12-31Northern Trust Corp1.18470.0034648446-85704-11.6739
2023-12-31Ameriprise Financial Inc1.02260.0049559702-9317-1.6374
Total 81.30268.111944500840+661631+1.5%

3.2. Funds holding Supernus Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29iShares Core S&P Small-Cap ETF6.81820.1431373193057420.1541
2023-12-31Macquarie US Small Cap Core Equity3.81070.8076208578400
2024-01-31Delaware Small Cap Core I3.76560.80622061077-24707-1.1845
2024-02-29Polar Capital Biotech S Inc3.19722.9556175000000
2024-02-29Vanguard Total Stock Mkt Idx Inv2.97060.00311625937-20419-1.2403
2024-02-29Vanguard Small Cap Index2.44410.02831337765123590.9325
2023-12-31Stephens SMID Select Growth2.24020.8831122616915917014.9175
2024-02-29iShares Russell 2000 ETF2.17450.05671190212-195-0.0164
2023-12-31Vanguard Explorer Inv1.83980.1363100700511258012.5869
2024-02-29Vanguard Small Cap Value Index Inv1.66650.05191213326300.2892
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.46490.02338018344860.0606
2024-01-31Loomis Sayles Small Cap Growth Instl1.3320.9152729095-9847-1.3326
2023-12-31Stephens Small Cap Growth1.23911.0572678229452667.1514
2024-02-29Congress Small Cap Growth Institutional1.04141.679257000000
2024-02-29International Biotechnology Ord0.99024.585754197300
2024-02-29BlackRock Advantage Small Cap Core Instl0.96570.4473528558-33393-5.9423
2024-02-29SPDR® Portfolio S&P 600 Sm Cap ETF0.89790.14224914771010.0206
2023-12-31Fidelity Small Cap Index0.89550.055849017768181.4105
2023-10-13Pictet Biopharmaceutical Mother0.83460.810245680015197649.857
2024-02-29iShares Russell 2000 Growth ETF0.78750.112843101931340.7324
Total 41.376215.699922647174+411701+1.8%

3.3. Insider Transactions

Insiders are holding 5.116% of the shares of Supernus Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-03-21Padmanabh P BhattSELL1449135.31
2024-03-19Padmanabh P BhattSELL1236435.31
2024-03-12Padmanabh P BhattSELL388432.99
2024-02-26Padmanabh P BhattSELL500030.21
2024-01-10Tami Tillotson MartinSELL800027.91
2023-11-15Frederick M HudsonSELL909328.5
2023-11-14Frank MottolaSELL111028.13
2023-08-30Tami Tillotson MartinSELL810032
2023-08-25Tami Tillotson MartinSELL513531.59

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Supernus Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.0020.598-100%-0.158+7630%0.419-100%0.401-101%
Book Value Per Share--16.66416.185+3%14.595+14%13.514+23%8.499+96%
Current Ratio--1.6991.537+11%1.185+43%2.070-18%2.399-29%
Debt To Asset Ratio--0.3460.354-2%0.499-31%0.475-27%0.457-24%
Debt To Equity Ratio--0.5290.577-8%0.998-47%0.936-43%0.907-42%
Dividend Per Share----0%-0%-0%-0%
Eps--0.021-0.004+117%0.154-86%0.298-93%0.283-92%
Free Cash Flow Per Share--0.8140.475+71%0.691+18%0.599+36%0.458+78%
Free Cash Flow To Equity Per Share--0.833-1.387+266%0.117+615%-0.001+100%0.334+149%
Gross Profit Margin---46.0447.302-731%-20.426-56%-2.801-94%-0.900-98%
Intrinsic Value_10Y_max--36.772--------
Intrinsic Value_10Y_min--24.678--------
Intrinsic Value_1Y_max--2.518--------
Intrinsic Value_1Y_min--1.952--------
Intrinsic Value_3Y_max--8.456--------
Intrinsic Value_3Y_min--6.352--------
Intrinsic Value_5Y_max--15.465--------
Intrinsic Value_5Y_min--11.250--------
Market Cap1604282850.000+0%1600420171.8601754378508.195-9%1905559524.968-16%1607391829.1330%1518658168.316+5%
Net Profit Margin--0.0070.002+285%0.056-87%0.136-95%0.162-96%
Operating Margin--0.1160.030+283%0.085+36%0.211-45%0.195-41%
Operating Ratio--0.8840.984-10%0.925-4%0.817+8%0.819+8%
Pb Ratio1.759+1%1.7371.915-9%2.241-22%2.189-21%5.329-67%
Pe Ratio344.868+1%340.515-36.177+111%131.390+159%37.189+816%38.167+792%
Price Per Share29.310+1%28.94030.700-6%32.690-11%28.672+1%27.398+6%
Price To Free Cash Flow Ratio9.006+1%8.8922.355+278%17.189-48%9.017-1%22.865-61%
Price To Total Gains Ratio-14339.066-1%-14158.055-3557.679-75%-11.457-100%-703.727-95%-316.803-98%
Quick Ratio--1.9951.484+34%1.385+44%2.366-16%2.784-28%
Return On Assets--0.001-0.001+183%0.006-85%0.012-93%0.031-97%
Return On Equity--0.0010.000+255%0.011-88%0.025-95%0.050-97%
Total Gains Per Share---0.0020.598-100%-0.158+7630%0.419-100%0.401-101%
Usd Book Value--921516000.000916441250.000+1%849071750.000+9%755854750.000+22%473250925.000+95%
Usd Book Value Change Per Share---0.0020.598-100%-0.158+7630%0.419-100%0.401-101%
Usd Book Value Per Share--16.66416.185+3%14.595+14%13.514+23%8.499+96%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps--0.021-0.004+117%0.154-86%0.298-93%0.283-92%
Usd Free Cash Flow--44994000.00027633500.000+63%40634250.000+11%33674800.000+34%25495500.000+76%
Usd Free Cash Flow Per Share--0.8140.475+71%0.691+18%0.599+36%0.458+78%
Usd Free Cash Flow To Equity Per Share--0.833-1.387+266%0.117+615%-0.001+100%0.334+149%
Usd Market Cap1604282850.000+0%1600420171.8601754378508.195-9%1905559524.968-16%1607391829.1330%1518658168.316+5%
Usd Price Per Share29.310+1%28.94030.700-6%32.690-11%28.672+1%27.398+6%
Usd Profit--1175000.000329000.000+257%9384250.000-87%16614150.000-93%16827600.000-93%
Usd Revenue--164314000.000151880250.000+8%168445500.000-2%138711500.000+18%98973800.000+66%
Usd Total Gains Per Share---0.0020.598-100%-0.158+7630%0.419-100%0.401-101%
 EOD+3 -5MRQTTM+23 -11YOY+21 -135Y+14 -2010Y+16 -18

4.2. Fundamental Score

Let's check the fundamental score of Supernus Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15344.868
Price to Book Ratio (EOD)Between0-11.759
Net Profit Margin (MRQ)Greater than00.007
Operating Margin (MRQ)Greater than00.116
Quick Ratio (MRQ)Greater than11.995
Current Ratio (MRQ)Greater than11.699
Debt to Asset Ratio (MRQ)Less than10.346
Debt to Equity Ratio (MRQ)Less than10.529
Return on Equity (MRQ)Greater than0.150.001
Return on Assets (MRQ)Greater than0.050.001
Total6/10 (60.0%)

4.3. Technical Score

Let's check the technical score of Supernus Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5039.244
Ma 20Greater thanMa 5031.230
Ma 50Greater thanMa 10031.352
Ma 100Greater thanMa 20029.649
OpenGreater thanClose30.030
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets1,408,977
Total Liabilities487,461
Total Stockholder Equity921,516
 As reported
Total Liabilities 487,461
Total Stockholder Equity+ 921,516
Total Assets = 1,408,977

Assets

Total Assets1,408,977
Total Current Assets493,113
Long-term Assets915,864
Total Current Assets
Cash And Cash Equivalents 75,054
Short-term Investments 179,820
Net Receivables 144,155
Inventory 77,408
Other Current Assets 16,676
Total Current Assets  (as reported)493,113
Total Current Assets  (calculated)493,113
+/-0
Long-term Assets
Property Plant Equipment 42,524
Goodwill 117,019
Long Term Investments 16,617
Intangible Assets 599,889
Long-term Assets Other 8,511
Long-term Assets  (as reported)915,864
Long-term Assets  (calculated)784,560
+/- 131,304

Liabilities & Shareholders' Equity

Total Current Liabilities290,196
Long-term Liabilities197,265
Total Stockholder Equity921,516
Total Current Liabilities
Short-term Debt 8,331
Accounts payable 1,964
Other Current Liabilities 279,901
Total Current Liabilities  (as reported)290,196
Total Current Liabilities  (calculated)290,196
+/- 0
Long-term Liabilities
Capital Lease Obligations 41,527
Long-term Liabilities Other 7,802
Long-term Liabilities  (as reported)197,265
Long-term Liabilities  (calculated)49,329
+/- 147,936
Total Stockholder Equity
Common Stock55
Retained Earnings 482,561
Accumulated Other Comprehensive Income -593
Other Stockholders Equity 439,493
Total Stockholder Equity (as reported)921,516
Total Stockholder Equity (calculated)921,516
+/-0
Other
Capital Stock55
Cash and Short Term Investments 254,874
Common Stock Shares Outstanding 55,301
Current Deferred Revenue0
Liabilities and Stockholders Equity 1,408,977
Net Debt -33,527
Net Invested Capital 921,516
Net Working Capital 202,917
Property Plant and Equipment Gross 28,935
Short Long Term Debt Total 41,527



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302009-12-312008-12-31
> Total Assets 
77,134
79,899
57,502
47,009
0
0
32,302
53,730
43,202
79,965
67,014
93,989
79,061
131,973
123,765
110,995
97,520
94,190
126,325
137,508
139,637
154,168
166,770
188,730
194,474
218,633
285,116
285,116
322,256
346,370
385,478
424,464
825,160
852,799
922,512
977,811
1,025,448
1,063,675
1,106,909
1,160,282
1,189,866
1,491,020
1,510,022
1,504,102
1,507,443
1,573,060
1,555,040
1,689,152
1,689,152
1,694,973
1,693,129
1,702,508
1,791,808
1,293,099
1,285,160
1,408,977
1,408,9771,285,1601,293,0991,791,8081,702,5081,693,1291,694,9731,689,1521,689,1521,555,0401,573,0601,507,4431,504,1021,510,0221,491,0201,189,8661,160,2821,106,9091,063,6751,025,448977,811922,512852,799825,160424,464385,478346,370322,256285,116285,116218,633194,474188,730166,770154,168139,637137,508126,32594,19097,520110,995123,765131,97379,06193,98967,01479,96543,20253,73032,3020047,00957,50279,89977,134
   > Total Current Assets 
0
72,880
51,243
39,814
0
0
24,910
49,399
38,417
77,805
62,889
91,741
76,332
110,617
102,862
97,161
79,929
71,981
102,968
108,892
101,505
105,740
102,551
105,977
93,955
114,140
138,203
138,203
149,757
165,492
191,330
228,451
583,246
284,516
390,557
493,487
419,967
390,911
427,082
472,644
557,048
557,153
552,015
630,417
586,023
639,244
668,375
601,590
601,590
625,120
663,886
734,151
883,340
423,538
449,360
493,113
493,113449,360423,538883,340734,151663,886625,120601,590601,590668,375639,244586,023630,417552,015557,153557,048472,644427,082390,911419,967493,487390,557284,516583,246228,451191,330165,492149,757138,203138,203114,14093,955105,977102,551105,740101,505108,892102,96871,98179,92997,161102,862110,61776,33291,74162,88977,80538,41749,39924,9100039,81451,24372,8800
       Cash And Cash Equivalents 
52,877
31,406
25,256
23,740
0
0
16,484
48,544
15,866
47,242
23,412
88,508
69,892
102,632
22,945
82,191
12,252
11,956
37,780
74,336
25,810
69,791
57,702
62,190
45,257
60,214
54,305
54,305
59,599
92,966
81,924
100,304
444,140
35,205
123,818
192,248
122,778
87,344
116,889
181,381
225,767
210,975
204,293
288,640
255,642
223,771
215,281
203,434
203,434
173,428
111,492
93,120
58,442
24,706
94,985
75,054
75,05494,98524,70658,44293,120111,492173,428203,434203,434215,281223,771255,642288,640204,293210,975225,767181,381116,88987,344122,778192,248123,81835,205444,140100,30481,92492,96659,59954,30554,30560,21445,25762,19057,70269,79125,81074,33637,78011,95612,25282,19122,945102,63269,89288,50823,41247,24215,86648,54416,4840023,74025,25631,40652,877
       Short-term Investments 
13,783
35,118
20,566
8,964
0
0
0
245
21,513
29,409
37,531
48,206
50,983
68,725
64,293
49,211
46,615
35,314
34,783
37,940
39,026
36,681
31,408
28,038
25,427
24,058
26,024
26,024
27,533
31,229
32,626
39,736
45,585
139,208
156,407
163,770
170,165
171,222
179,808
165,692
175,104
163,839
147,657
133,893
135,459
186,070
228,571
136,246
136,246
187,359
280,297
368,214
170,126
126,950
105,204
179,820
179,820105,204126,950170,126368,214280,297187,359136,246136,246228,571186,070135,459133,893147,657163,839175,104165,692179,808171,222170,165163,770156,407139,20845,58539,73632,62631,22927,53326,02426,02424,05825,42728,03831,40836,68139,02637,94034,78335,31446,61549,21164,29368,72550,98348,20637,53129,40921,5132450008,96420,56635,11813,783
       Net Receivables 
0
3,742
3,119
158
0
0
3,978
128
0
0
500
675
1,650
537
8,190
5,054
10,361
11,350
15,796
17,270
19,271
17,900
23,603
25,908
30,651
34,281
36,220
36,220
38,885
51,157
56,166
65,586
67,864
74,842
77,753
102,922
79,950
84,564
86,699
87,332
119,195
126,559
133,107
140,877
127,065
137,275
133,676
148,932
148,932
158,063
164,086
165,497
143,568
136,556
141,764
144,155
144,155141,764136,556143,568165,497164,086158,063148,932148,932133,676137,275127,065140,877133,107126,559119,19587,33286,69984,56479,950102,92277,75374,84267,86465,58656,16651,15738,88536,22036,22034,28130,65125,90823,60317,90019,27117,27015,79611,35010,3615,0548,1905371,650675500001283,978001583,1193,7420
       Inventory 
0
2,347
1,951
6,755
0
0
3,995
389
0
0
26
1,152
3,113
4,315
5,188
7,152
7,957
10,101
11,145
13,441
13,702
13,592
14,742
12,587
13,044
16,373
17,453
17,453
19,167
16,623
14,947
16,304
19,075
20,680
23,280
25,659
26,518
26,024
25,504
26,628
24,418
35,338
42,465
48,325
50,226
58,391
60,155
85,959
85,959
84,860
83,165
91,541
91,147
90,560
83,480
77,408
77,40883,48090,56091,14791,54183,16584,86085,95985,95960,15558,39150,22648,32542,46535,33824,41826,62825,50426,02426,51825,65923,28020,68019,07516,30414,94716,62319,16717,45317,45316,37313,04412,58714,74213,59213,70213,44111,14510,1017,9577,1525,1884,3153,1131,15226003893,995006,7551,9512,3470
   > Long-term Assets 
0
7,019
6,259
7,195
0
0
7,392
4,331
4,785
2,160
4,125
2,248
2,729
21,356
20,903
13,834
17,591
22,209
23,357
28,616
38,132
48,428
64,219
82,753
100,519
104,493
146,913
146,913
172,499
180,878
194,148
196,013
241,914
568,283
531,955
484,324
605,481
672,764
679,827
687,638
632,818
933,867
958,007
873,685
921,420
933,816
886,665
1,087,562
1,087,562
1,069,853
1,029,243
968,357
908,468
869,561
835,800
915,864
915,864835,800869,561908,468968,3571,029,2431,069,8531,087,5621,087,562886,665933,816921,420873,685958,007933,867632,818687,638679,827672,764605,481484,324531,955568,283241,914196,013194,148180,878172,499146,913146,913104,493100,51982,75364,21948,42838,13228,61623,35722,20917,59113,83420,90321,3562,7292,2484,1252,1604,7854,3317,392007,1956,2597,0190
       Property Plant Equipment 
1,988
1,859
1,469
1,249
0
0
1,289
1,310
1,183
1,146
1,384
1,421
1,687
2,247
2,480
2,554
2,648
2,590
2,500
2,448
2,481
2,908
3,210
3,874
3,866
4,193
4,318
4,318
4,342
4,572
4,688
5,124
5,003
4,897
6,930
4,095
24,275
23,667
28,757
38,347
39,922
61,709
60,090
37,824
37,950
17,065
16,471
52,320
16,955
16,317
15,872
15,173
14,611
14,186
13,688
42,524
42,52413,68814,18614,61115,17315,87216,31716,95552,32016,47117,06537,95037,82460,09061,70939,92238,34728,75723,66724,2754,0956,9304,8975,0035,1244,6884,5724,3424,3184,3184,1933,8663,8743,2102,9082,4812,4482,5002,5902,6482,5542,4802,2471,6871,4211,3841,1461,1831,3101,289001,2491,4691,8591,988
       Goodwill 
0
0
0
0
0
0
0
0
0
798
740
683
626
568
817
1,158
2,157
3,083
4,135
5,434
7,839
11,597
16,627
976
16,108
15,785
15,526
16,490
29,450
28,989
37,162
36,019
34,858
33,794
32,572
31,368
30,063
28,787
26,101
24,840
23,579
88,095
89,143
77,911
77,911
77,963
77,963
117,516
117,516
115,414
117,383
117,019
117,019
117,019
117,019
117,019
117,019117,019117,019117,019117,019117,383115,414117,516117,51677,96377,96377,91177,91189,14388,09523,57924,84026,10128,78730,06331,36832,57233,79434,85836,01937,16228,98929,45016,49015,52615,78516,10897616,62711,5977,8395,4344,1353,0832,1571,158817568626683740798000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
1,804
0
0
16,072
15,215
8,756
11,662
15,462
15,763
19,816
27,315
33,488
43,967
55,009
68,790
67,809
67,044
75,410
89,163
104,632
123,123
133,638
175,064
503,312
460,304
418,798
522,551
593,754
596,442
591,773
534,712
358,673
388,185
350,359
416,566
445,473
405,479
119,166
119,166
147,373
131,937
93,896
54,157
37,478
25,125
16,617
16,61725,12537,47854,15793,896131,937147,373119,166119,166405,479445,473416,566350,359388,185358,673534,712591,773596,442593,754522,551418,798460,304503,312175,064133,638123,123104,63289,16375,41067,04467,80968,79055,00943,96733,48827,31519,81615,76315,46211,6628,75615,21516,072001,8040000000000
       Intangible Assets 
0
1,371
1,199
1,142
0
0
970
912
855
798
740
683
626
568
817
1,158
2,157
3,083
4,135
5,434
7,839
11,597
16,627
976
16,108
15,270
15,526
15,526
29,450
28,989
37,162
36,019
34,858
33,794
32,572
31,368
30,063
28,787
26,101
24,840
23,579
408,272
402,265
442,253
358,736
352,628
346,619
784,693
784,693
743,405
722,761
702,463
682,497
662,389
641,147
599,889
599,889641,147662,389682,497702,463722,761743,405784,693784,693346,619352,628358,736442,253402,265408,27223,57924,84026,10128,78730,06331,36832,57233,79434,85836,01937,16228,98929,45015,52615,52615,27016,10897616,62711,5977,8395,4344,1353,0832,1571,158817568626683740798855912970001,1421,1991,3710
       Long-term Assets Other 
0
3,789
3,591
4,804
0
0
5,133
2,109
2,747
216
55
144
416
928
360
1,519
360
361
360
6,352
497
12,032
415
391
311
320
332
17,769
11,681
12,236
368
389
735
752
782
380
625
581
574
615
538
-18,598
-19,617
43,249
-1,485
7,701
5,987
49,232
49,232
-11,969
-16,874
-95,067
-9,484
-5,811
3,597
8,511
8,5113,597-5,811-9,484-95,067-16,874-11,96949,23249,2325,9877,701-1,48543,249-19,617-18,59853861557458162538078275273538936812,23611,68117,76933232031139141512,0324976,3523603613601,519360928416144552162,7472,1095,133004,8043,5913,7890
       Deferred Long Term Asset Charges 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
22,503
11,444
16,386
59,693
61,589
49,194
42,336
28,807
20,843
26,254
25,528
31,367
29,683
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000029,68331,36725,52826,25420,84328,80742,33649,19461,58959,69316,38611,44422,50300000000000000000000000
> Total Liabilities 
0
86,055
93,419
91,329
0
0
104,825
44,287
42,928
41,985
42,383
36,419
37,789
96,081
111,312
77,531
68,507
60,821
60,206
66,154
45,053
51,803
57,334
69,855
66,335
77,611
111,745
111,745
116,192
116,973
133,815
156,984
473,291
462,307
500,576
524,788
545,430
540,771
549,652
564,854
576,483
825,046
801,143
759,244
752,999
787,481
744,572
873,301
873,301
853,539
840,331
816,304
879,658
373,191
372,969
487,461
487,461372,969373,191879,658816,304840,331853,539873,301873,301744,572787,481752,999759,244801,143825,046576,483564,854549,652540,771545,430524,788500,576462,307473,291156,984133,815116,973116,192111,745111,74577,61166,33569,85557,33451,80345,05366,15460,20660,82168,50777,531111,31296,08137,78936,41942,38341,98542,92844,287104,8250091,32993,41986,0550
   > Total Current Liabilities 
8,274
10,033
17,408
15,207
0
0
16,509
18,770
19,912
21,881
24,590
22,983
27,008
16,024
25,071
26,400
27,102
19,187
22,126
27,493
26,855
36,414
43,128
56,097
54,124
65,572
71,647
71,647
82,003
85,524
104,956
123,000
119,088
103,934
138,346
161,353
151,706
143,971
149,717
160,587
168,335
269,276
299,606
245,108
240,812
283,447
234,711
315,379
315,379
735,536
725,987
687,958
731,545
252,590
287,534
290,196
290,196287,534252,590731,545687,958725,987735,536315,379315,379234,711283,447240,812245,108299,606269,276168,335160,587149,717143,971151,706161,353138,346103,934119,088123,000104,95685,52482,00371,64771,64765,57254,12456,09743,12836,41426,85527,49322,12619,18727,10226,40025,07116,02427,00822,98324,59021,88119,91218,77016,5090015,20717,40810,0338,274
       Short-term Debt 
0
0
0
0
0
0
3,506
6,775
9,171
10,747
11,490
11,809
12,137
-12,057
-14,706
-18,518
-14,831
-19,044
-21,983
26,223
0
0
0
7,085
0
0
0
66,413
72,015
72,663
93,153
111,586
318,225
321,920
0
0
3,250
3,357
3,145
2,825
3,456
7,761
7,353
3,760
4,242
5,900
5,904
0
6,477
400,909
401,438
401,968
480,863
8,019
8,480
8,331
8,3318,4808,019480,863401,968401,438400,9096,47705,9045,9004,2423,7607,3537,7613,4562,8253,1453,3573,25000321,920318,225111,58693,15372,66372,01566,4130007,08500026,223-21,983-19,044-14,831-18,518-14,706-12,05712,13711,80911,49010,7479,1716,7753,506000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
26,223
0
0
0
7,085
0
0
0
4,165
3,310
1,472
0
0
318,225
321,920
0
0
3,250
0
0
0
0
0
0
0
0
0
0
0
0
400,909
401,438
401,968
480,863
0
0
0
000480,863401,968401,438400,9090000000000003,25000321,920318,225001,4723,3104,1650007,08500026,2230000000000000000000
       Accounts payable 
4,468
6,245
14,092
11,263
0
0
9,149
10,078
9,337
9,175
10,485
10,666
10,903
11,732
14,472
18,314
14,658
19,044
21,983
1,863
859
4,518
2,812
4,314
2,646
2,243
29,404
2,685
5,056
7,577
6,262
6,844
3,333
2,943
9,838
3,195
7,240
4,081
3,090
10,141
3,124
5,515
11,193
78,934
70,099
79,993
72,286
9,331
117,683
133,000
110,302
96,342
95,345
4,400
3,389
1,964
1,9643,3894,40095,34596,342110,302133,000117,6839,33172,28679,99370,09978,93411,1935,5153,12410,1413,0904,0817,2403,1959,8382,9433,3336,8446,2627,5775,0562,68529,4042,2432,6464,3142,8124,5188591,86321,98319,04414,65818,31414,47211,73210,90310,66610,4859,1759,33710,0789,1490011,26314,0926,2454,468
       Other Current Liabilities 
3,806
3,788
3,316
3,944
0
0
3,719
1,685
1,172
1,594
2,039
508
3,968
12,057
14,706
18,518
14,831
19,044
21,983
25,487
25,853
31,753
40,173
51,607
51,270
63,121
42,243
2,342
4,645
4,997
5,254
4,283
115,755
100,991
128,508
158,158
2,426
2,668
2,959
115,558
3,658
28,025
87,798
127,199
41,977
29,856
30,377
100,099
105,864
142,314
156,083
139,839
155,337
20,720
46,590
279,901
279,90146,59020,720155,337139,839156,083142,314105,864100,09930,37729,85641,977127,19987,79828,0253,658115,5582,9592,6682,426158,158128,508100,991115,7554,2835,2544,9974,6452,34242,24363,12151,27051,60740,17331,75325,85325,48721,98319,04414,83118,51814,70612,0573,9685082,0391,5941,1721,6853,719003,9443,3163,7883,806
   > Long-term Liabilities 
0
76,022
76,011
76,122
0
0
88,316
25,517
23,016
20,104
17,793
13,436
10,781
80,057
86,241
51,131
41,405
41,634
38,080
38,661
18,198
15,389
14,206
13,758
12,211
12,039
40,098
40,098
34,189
31,449
28,859
33,984
354,203
358,373
362,230
363,435
393,724
396,800
399,935
404,267
408,148
555,770
501,537
514,136
512,187
504,034
509,861
557,922
557,922
118,003
114,344
128,346
148,113
120,601
85,435
197,265
197,26585,435120,601148,113128,346114,344118,003557,922557,922509,861504,034512,187514,136501,537555,770408,148404,267399,935396,800393,724363,435362,230358,373354,20333,98428,85931,44934,18940,09840,09812,03912,21113,75814,20615,38918,19838,66138,08041,63441,40551,13186,24180,05710,78113,43617,79320,10423,01625,51788,3160076,12276,01176,0220
       Long term Debt Total 
0
0
0
0
0
0
0
0
19,926
17,061
14,116
11,088
7,975
59,100
60,175
34,393
28,358
28,671
26,497
26,947
11,708
8,762
7,939
7,085
5,627
5,699
5,772
4,165
3,310
1,472
0
0
318,225
321,920
325,666
329,462
333,310
337,210
341,163
345,170
349,232
353,349
357,521
361,751
366,038
370,383
374,788
0
379,252
0
0
0
0
0
0
0
0000000379,2520374,788370,383366,038361,751357,521353,349349,232345,170341,163337,210333,310329,462325,666321,920318,225001,4723,3104,1655,7725,6995,6277,0857,9398,76211,70826,94726,49728,67128,35834,39360,17559,1007,97511,08814,11617,06119,92600000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
-3,506
-6,775
-9,171
-10,747
-11,490
-11,809
-12,137
12,057
14,706
18,518
14,831
19,044
21,983
-26,223
0
0
0
-7,085
0
0
0
-66,413
-72,015
-72,663
-93,153
-111,586
-318,225
-321,920
0
0
27,824
27,535
27,256
30,440
30,804
48,490
48,811
24,819
24,290
30,243
31,357
47,775
33,414
-363,829
-365,410
-365,970
-444,352
34,177
33,841
33,196
33,19633,84134,177-444,352-365,970-365,410-363,82933,41447,77531,35730,24324,29024,81948,81148,49030,80430,44027,25627,53527,82400-321,920-318,225-111,586-93,153-72,663-72,015-66,413000-7,085000-26,22321,98319,04414,83118,51814,70612,057-12,137-11,809-11,490-10,747-9,171-6,775-3,506000000
       Deferred Long Term Asset Charges 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
22,503
11,444
16,386
59,693
61,589
49,194
42,336
28,807
20,843
26,254
25,528
31,367
29,683
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000029,68331,36725,52826,25420,84328,80742,33649,19461,58959,69316,38611,44422,50300000000000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
1,658
1,691
1,833
1,788
1,860
2,158
2,401
2,677
2,101
2,784
3,015
3,876
2,561
3,355
34,102
34,356
34,012
33,177
32,485
31,291
29,491
28,684
27,638
32,835
35,978
36,453
36,564
33,973
60,414
59,590
58,772
59,097
58,916
118,215
106,075
45,800
114,407
64,522
100,927
52,017
35,637
21,610
56,180
42,539
98,445
76,301
16,370
7,802
7,80216,37076,30198,44542,53956,18021,61035,63752,017100,92764,522114,40745,800106,075118,21558,91659,09758,77259,59060,41433,97336,56436,45335,97832,83527,63828,68429,49131,29132,48533,17734,01234,35634,1023,3552,5613,8763,0152,7842,1012,6772,4012,1581,8601,7881,8331,6911,65800000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
1,432
1,352
1,844
560
946
18,799
23,665
14,061
10,946
10,179
8,568
7,838
3,929
3,272
2,323
2,244
2,193
2,018
1,841
1,615
1,388
1,293
1,221
1,149
0
0
0
0
0
0
0
0
0
35,716
37,941
35,215
31,742
32,986
34,146
0
85,355
59,313
58,164
49,809
49,668
44,300
0
0
0044,30049,66849,80958,16459,31385,355034,14632,98631,74235,21537,94135,7160000000001,1491,2211,2931,3881,6151,8412,0182,1932,2442,3233,2723,9297,8388,56810,17910,94614,06123,66518,7999465601,8441,3521,43200000000
> Total Stockholder Equity
0
-6,156
-35,917
-44,320
0
0
-72,523
9,443
274
37,980
24,631
57,570
41,272
35,892
12,453
33,464
29,013
33,369
66,119
71,354
94,584
102,365
109,436
118,875
128,139
141,022
173,371
173,371
206,064
229,397
251,663
267,480
351,869
390,492
421,936
453,023
480,018
522,904
557,257
595,428
613,383
665,974
708,879
744,858
754,444
785,579
810,468
815,851
815,851
841,434
852,798
886,204
912,150
919,908
912,191
921,516
921,516912,191919,908912,150886,204852,798841,434815,851815,851810,468785,579754,444744,858708,879665,974613,383595,428557,257522,904480,018453,023421,936390,492351,869267,480251,663229,397206,064173,371173,371141,022128,139118,875109,436102,36594,58471,35466,11933,36929,01333,46412,45335,89241,27257,57024,63137,9802749,443-72,52300-44,320-35,917-6,1560
   Retained Earnings 
0
-55,323
-85,210
-93,786
0
0
-121,947
-39,971
-49,247
-59,259
-72,742
-86,255
-104,669
-132,026
-156,122
-178,528
-194,071
-190,870
-163,012
-158,657
-157,740
-155,734
-151,512
-144,641
-139,654
-129,636
-98,607
-98,607
-73,810
-56,442
-40,481
-26,823
1,851
32,588
60,599
86,492
104,832
137,559
166,419
199,548
221,066
255,733
295,730
326,498
332,192
355,918
377,480
379,922
379,922
454,015
455,764
481,245
498,193
497,362
481,386
482,561
482,561481,386497,362498,193481,245455,764454,015379,922379,922377,480355,918332,192326,498295,730255,733221,066199,548166,419137,559104,83286,49260,59932,5881,851-26,823-40,481-56,442-73,810-98,607-98,607-129,636-139,654-144,641-151,512-155,734-157,740-158,657-163,012-190,870-194,071-178,528-156,122-132,026-104,669-86,255-72,742-59,259-49,247-39,971-121,94700-93,786-85,210-55,3230
   Accumulated Other Comprehensive Income 
0
2
-3,698
-3,938
0
0
1
1
8
6
-29
-57
-89
-235
-81
-5,591
1
1
-35
-154
-65
-151
-107
-488
168
549
-7,826
127
32
216
252
-747
-2,291
-4,119
-4,111
-3,158
1,427
5,924
7,261
7,417
-166
11,359
9,700
8,975
6,249
5,433
4,209
0
1,539
-2,220
-4,046
-3,210
-2,329
-1,775
-1,206
-593
-593-1,206-1,775-2,329-3,210-4,046-2,2201,53904,2095,4336,2498,9759,70011,359-1667,4177,2615,9241,427-3,158-4,111-4,119-2,291-74725221632127-7,826549168-488-107-151-65-154-3511-5,591-81-235-89-57-29681100-3,938-3,69820
   Capital Surplus 
0
0
0
0
0
0
0
0
49,462
97,209
97,378
143,851
145,999
168,122
168,625
211,952
223,041
224,196
229,123
230,122
252,341
258,202
261,006
263,955
267,576
270,059
271,801
276,127
279,792
285,572
291,841
294,999
352,257
361,971
365,396
369,637
373,707
379,369
383,525
388,410
392,430
398,829
403,396
409,332
415,950
424,175
428,726
0
434,337
389,586
401,026
408,115
416,232
424,266
0
0
00424,266416,232408,115401,026389,586434,3370428,726424,175415,950409,332403,396398,829392,430388,410383,525379,369373,707369,637365,396361,971352,257294,999291,841285,572279,792276,127271,801270,059267,576263,955261,006258,202252,341230,122229,123224,196223,041211,952168,625168,122145,999143,85197,37897,20949,46200000000
   Treasury Stock00000000000000000000000000000000000000000000000000000000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue607,521
Cost of Revenue-168,638
Gross Profit438,883438,883
 
Operating Income (+$)
Gross Profit438,883
Operating Expense-425,480
Operating Income13,40313,403
 
Operating Expense (+$)
Research Development89,119
Selling General Administrative107,175
Selling And Marketing Expenses229,186
Operating Expense425,480425,480
 
Net Interest Income (+$)
Interest Income10,867
Interest Expense-2,415
Other Finance Cost-1,594
Net Interest Income6,858
 
Pretax Income (+$)
Operating Income13,403
Net Interest Income6,858
Other Non-Operating Income Expenses0
Income Before Tax (EBT)2,76924,037
EBIT - interestExpense = 10,988
2,769
3,731
Interest Expense2,415
Earnings Before Interest and Taxes (EBIT)13,4035,184
Earnings Before Interest and Taxes (EBITDA)98,262
 
After tax Income (+$)
Income Before Tax2,769
Tax Provision-11,297
Net Income From Continuing Ops25,622-8,528
Net Income1,316
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses594,118
Total Other Income/Expenses Net-10,634-6,858
 

Technical Analysis of Supernus
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Supernus. The general trend of Supernus is BULLISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Supernus's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (14.3%) Bearish trend (-14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Supernus Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 32.29 < 34.49 < 35.44.

The bearish price targets are: 28.63 > 26.78 > 26.47.

Tweet this
Supernus Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Supernus Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 8/14.
The longshort score for the Moving Averages is 2/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Supernus Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Supernus Pharmaceuticals Inc. The current macd is -0.73653116.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Supernus price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Supernus. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Supernus price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Supernus Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartSupernus Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Supernus Pharmaceuticals Inc. The current adx is 21.12.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Supernus shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Supernus Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Supernus Pharmaceuticals Inc. The current sar is 28.76.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Supernus Pharmaceuticals Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Supernus Pharmaceuticals Inc. The current rsi is 39.24. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending down: The RSI is trending down. -1
Supernus Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartSupernus Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Supernus Pharmaceuticals Inc. The current phase is Oversold in bull market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Supernus price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Supernus Pharmaceuticals Inc Daily Stochastic Oscillator ChartSupernus Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Supernus Pharmaceuticals Inc. The current cci is -77.07751556.

Supernus Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartSupernus Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Supernus Pharmaceuticals Inc. The current cmo is -28.6429801.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Supernus Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartSupernus Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Supernus Pharmaceuticals Inc. The current willr is -84.78747204.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Supernus Pharmaceuticals Inc Daily Williams %R ChartSupernus Pharmaceuticals Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Supernus Pharmaceuticals Inc. The current atr is 1.22617312.

Supernus Pharmaceuticals Inc Daily Average True Range (ATR) ChartSupernus Pharmaceuticals Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Supernus Pharmaceuticals Inc. The current obv is 2,628,777.

Supernus Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartSupernus Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Supernus Pharmaceuticals Inc. The current mfi is 32.14.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Supernus Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartSupernus Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Supernus Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-04SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-08CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-05WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-16SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-18WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-23STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-31MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-12CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-27STOCH LONG EXITThe %K line crosses below the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-11WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-14RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-25CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-12STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-04-25STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside

6.3. Candlestick Patterns

Supernus Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Supernus Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5039.244
Ma 20Greater thanMa 5031.230
Ma 50Greater thanMa 10031.352
Ma 100Greater thanMa 20029.649
OpenGreater thanClose30.030
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Supernus with someone you think should read this too:
  • Are you bullish or bearish on Supernus? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Supernus? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Supernus Pharmaceuticals Inc

I send you an email if I find something interesting about Supernus Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Supernus Pharmaceuticals Inc.

Receive notifications about Supernus Pharmaceuticals Inc in your mailbox!